|
|
|
|
| LEADER |
02154nam a2200277 u 4500 |
| 001 |
EB002000716 |
| 003 |
EBX01000000000000001163617 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 100 |
1 |
|
|a Peterson, Kim
|
| 245 |
0 |
0 |
|a Drug class review: Newer antiemetics
|h Elektronische Ressource
|b final report update 1
|c Kimberly Peterson ... [et al.]
|
| 246 |
3 |
1 |
|a Newer antiemetics
|
| 260 |
|
|
|a Portland, OR
|b Oregon Health & Science University
|c 2008, c2008
|
| 300 |
|
|
|a 1 online resource
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 710 |
2 |
|
|a Drug Effectiveness Review Project
|
| 710 |
2 |
|
|a Oregon Health & Science University
|b Evidence-based Practice Center
|
| 710 |
2 |
|
|a Oregon Health & Science University
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Drug class reviews
|
| 500 |
|
|
|a Title from PDF title page (viewed July 19, 2011). - "January 2009."
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK47160
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a Nausea and vomiting are major concerns for patients undergoing chemotherapy, radiation therapy and surgery with general anesthesia. Risk factors associated with chemotherapy-induced nausea and vomiting include emetogenicity of the chemotherapy regimen, dose, speed of intravenous infusion, female gender, age under 50 years, history of ethanol consumption, and history of prior chemotherapy. Factors predictive of radiation therapy-induced nausea and vomiting include site of irradiation (in particular, total body irradiation and radiation fields that include the abdomen), total field size, dose per fraction, age, and predisposition for emesis (history of sickness during pregnancy or motion sickness). Female gender, a history of motion sickness or prior postoperative nausea and vomiting, nonsmoking status, and use of postoperative opioids have been suggested as factors predictive of postoperative nausea and vomiting. The objective of this review was to evaluate the comparative effectiveness and harms of newer antiemetic drugs including the 5-HT3 and NK-1 antagonists
|